A recent study characterizes silent seizures in a mouse model of Dravet syndrome and identifies a new brain area that could be targeted to stop them. As early as 3 months of age, infants with a severe ...
Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% ...
New Treatment Option for Seizures Associated with Lennox-Gastaut Syndrome WOODCLIFF LAKE, N.J., Nov. 14 /PRNewswire/ -- Eisai Corporation of North America announced today that the U.S. Food and Drug ...
Active ingredient: Rufinamide 200 mg, 400 mg; scored tabs. Indication: Adjunctive treatment of seizures in Lennox-Gastaut syndrome (LGS). Pharmacology: LGS is a seizure disorder characterized by ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure =3s, p = 0.012 DEE: 63.3% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results